-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Initiates Coverage On Denali Therapeutics with Overweight Rating, Announces Price Target of $35

Benzinga·11/13/2026 13:06:10
Listen to the news
Wells Fargo analyst Benjamin Burnett initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Overweight rating and announces Price Target of $35.